Among the fewer than half of patients with cancer who received opioid fills, a relatively small proportion (2.5%) had potentially problematic opioid use.
Linda Simoni-Wastila, PhD, MSPH
Advertisement
Articles by Linda Simoni-Wastila, PhD, MSPH
Advertisement
Latest Updated Articles
- Patterns of Opioid Use in Commercially Insured Patients With Cancer
Published: May 3rd 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5
